Semaglutide vs. Tirzepatide: How Do They Compare?

Semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management) is a GLP-1 receptor agonist. It mimics a single gut hormone — GLP-1 — that helps regulate appetite, slows digestion, and supports insulin release.

Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight management and sleep apnea) is a dual GIP/GLP-1 receptor agonist. It activates receptors for twohormones — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — engaging an additional metabolic pathway that semaglutide doesn't touch.

That extra mechanism is the main reason tirzepatide tends to produce larger average results in clinical trials, though “larger on average” doesn't mean better for every individual.

For years, comparisons between the two drugs relied on cross-trial comparisons — not ideal, since different trials enroll different populations. That changed with SURMOUNT-5, a phase 3b trial that directly compared the two medications in the same group of adults with obesity or overweight (without type 2 diabetes).

The results, at 72 weeks:

• Tirzepatide (max tolerated dose, 10mg or 15mg): average weight reduction of roughly 20%
• Semaglutide (max tolerated dose, 1.7mg or 2.4mg): average weight reduction of roughly 14%

Tirzepatide also outperformed semaglutide on secondary measures, including waist circumference reduction and the proportion of patients reaching higher weight-loss thresholds (10%, 15%, 20%, and 25% body weight reduction). Improvements in blood pressure, blood sugar markers, and cholesterol were also somewhat greater in the tirzepatide group.

Important context: these are group averages from a controlled trial. Individual response varies substantially — some people respond very well to semaglutide and less dramatically to tirzepatide, or vice versa. Averages describe populations, not guarantees for any one person.

Both medications share a similar side effect profile, largely because they work through overlapping mechanisms (slowed digestion, altered appetite signaling):

Neither medication has a clearly “gentler” side effect profile across the board — tolerability tends to be individual, and both require gradual dose titration to manage GI symptoms.

Both are once-weekly subcutaneous injections with a gradual dose titration schedule designed to minimize side effects. Semaglutide and tirzepatide use different dosing scales and titration schedules, so comparing “mg to mg” across the two isn't meaningful — what matters is the response and tolerability at the dose a prescriber determines is right for you.

Both medications are FDA-approved for:

• Type 2 diabetes (Ozempic / Mounjaro)
• Chronic weight management (Wegovy / Zepbound)

Tirzepatide (Zepbound) additionally holds an FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity — an indication semaglutide does not currently carry. Semaglutide, on the other hand, has an FDA-approved indication for cardiovascular risk reduction in adults with established heart disease and obesity or overweight, which tirzepatide does not currently hold.

There's no universal answer — the right choice depends on several factors best worked through with a licensed provider:

• Treatment goals: If sleep apnea is a factor, tirzepatide's specific approval may be relevant. If cardiovascular risk reduction is the priority, semaglutide's approval may be more directly applicable.
• Prior response: Some people have already tried one medication and are considering switching based on their own results or tolerability.
• Side effect tolerance: Individual experience with GI side effects can differ meaningfully between the two, even though the overall profiles look similar on paper.
• Health history: Certain medical conditions may make one option more or less appropriate.
• Cost and access: Insurance coverage, manufacturer savings programs, and out-of-pocket pricing can vary significantly between the two and often plays a real role in the decision.

Tirzepatide's dual-hormone mechanism has shown an edge in head-to-head trial data, with meaningfully greater average weight loss than semaglutide at comparable maximum doses. But “more effective on average” isn't the same as “right for everyone” — side effect tolerance, other health conditions, treatment goals, and individual response all factor into which medication makes sense for a given person. That decision is best made with a licensed provider who can evaluate your full health picture.